2-(2-Methylpropyl)-4,5-dihydro-1H-imidazol | 76500-88-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 亚胺内酰胺
• 英文名称: 2-(2-Methylpropyl)-4,5-dihydro-1H-imidazol
• 英文别名: 2-isobutyl-2-imidazoline；2-(2-methylpropyl)-4,5-dihydro-1H-imidazole
• CAS: 76500-88-4
• 化学式: C₇H₁₄N₂
• 分子量: 126.202
• InChiKey: ACSCPCCHMWGVCG-UHFFFAOYSA-N

物化性质

• 沸点：
  106-108 °C(Press: 16 Torr)
• 密度：
  1.01±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  24.4
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(2-Methylpropyl)-4,5-dihydro-1H-imidazol 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 生成 1,3-Dimethyl-2-(2-methylpropyliden)imidazolidin
  参考文献：
  名称：

  Gruseck, Ursula; Heuschmann, Manfred, Chemische Berichte, 1987, vol. 120, p. 2053 - 2064

  摘要：

  DOI：
• 作为产物：
  描述：

  异戊酸 、 乙二胺 在 iron oxide 作用下， 以 水 、 苯 为溶剂， 反应 4.0h， 以70%的产率得到2-(2-Methylpropyl)-4,5-dihydro-1H-imidazol
  参考文献：
  名称：

  Colloid and nanosized catalysts in organic synthesis: XIII. Synthesis of 2-R-2-imidazolines catalyzed by copper and iron oxide nanoparticles

  摘要：

  The reaction of carboxylic acids with ethylenediamine catalyzed by copper or iron oxide nanoparticles proceeds at 80A degrees C with azeotropic water distilling off during 2-8 h to form 2-R-2-imidazolines. Acyl and diacyl derivatives of ethylenediamine are formed in the reaction as side products.

  DOI：

  10.1134/s1070363216020122

文献信息

• IMIDAZOLINYLMETHYL ARYL SULFONAMIDE
  申请人：O'Yang Counde

  公开号：US20090197932A1

  公开（公告）日：2009-08-06

  This invention relates to an alpha-1A receptor partial agonist, which is represented by Formula I: and pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing formula I, methods for their use as therapeutic agents, and methods of preparation thereof.

  这项发明涉及一种α-1A受体部分激动剂，其表示为公式I：以及其药用盐或溶剂合物。该发明还涉及含有公式I的药物组合物，以及将其用作治疗剂的方法和其制备方法。
• IMIDAZOLINYLMETHY ARYL SULFONAMIDE
  申请人：O'Yang Counde

  公开号：US20090197931A1

  公开（公告）日：2009-08-06

  This invention relates to an alpha-1 A receptor partial agonist, which is represented by Formula I: and pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing formula I, methods for their use as therapeutic agents, and methods of preparation thereof.

  这项发明涉及一种α-1A受体部分激动剂，其由化学式I代表，并且其药学上可接受的盐或溶剂。该发明还涉及含有化学式I的药物组合物，以及将其用作治疗剂的方法和其制备方法。
• Method for the preparation of imidazoles
  申请人：TEXACO DEVELOPMENT CORPORATION

  公开号：EP0378910A1

  公开（公告）日：1990-07-25

  Imidazolines can be dehydrogenated into the corresponding imidazoles, in high yield and with good selectivity by contacting the imidazoline at 160 to 300°C and up to 3.55 MPa, with a catalyst comprising nickel-copper, nickel-­chromium or nickel-copper-chromium. If desired the imidazoline can be generated by reaction of corresponding diamines with carboxylic acids or nitriles, and converted directly into the imidazoles without being isolated.

  将咪唑啉与由镍-铜、镍-铬或镍-铜-铬组成的催化剂在 160 至 300 摄氏度和高达 3.55 兆帕的压力下接触，可将咪唑啉脱氢成相应的咪唑，产率高，选择性好。 如果需要，还可以通过相应的二胺与羧酸或腈反应生成咪唑啉，并直接转化为咪唑，而无需分离。
• Curable epoxy resin compositions
  申请人：TEXACO CHEMICAL COMPANY

  公开号：EP0525940A2

  公开（公告）日：1993-02-03

  Epoxy resins can be cured by complexes of lactones with imidazoles. Preferred lactones are: in which n is from 2 to 5 and each R, which may be the same or different, is hydrogen or alkyl having 1 to 18 carbon atoms. Preferred imidazoles are: wherein R1 is hydrogen, alkyl having 1 to 18 carbon atoms, or aryl, and R2 is alkyl having 1 to 18 carbon atoms. The complexes are less reactive than the imidazole used alone, making them suitable for use in applications where an extended working time is needed.

  环氧树脂可通过内酯与咪唑的络合物固化。 首选的内酯有 其中 n 为 2 至 5，每个 R（可以相同或不同）为氢或具有 1 至 18 个碳原子的烷基。 优选的咪唑类化合物有 其中 R1 是氢、具有 1 至 18 个碳原子的烷基或芳基，R2 是具有 1 至 18 个碳原子的烷基。 与单独使用咪唑相比，复合物的反应性较低，因此适合用于需要延长工作时间的场合。
• Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
  申请人：Crinetics Pharmaceuticals, Inc.

  公开号：US10562884B2

  公开（公告）日：2020-02-18

  Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.

  本文描述了黑色素皮质素亚型-2 受体（MC2R）调节剂化合物、制造此类化合物的方法、包含此类化合物的药物组合物和药物，以及使用此类化合物治疗可从调节 MC2R 活性中获益的病症、疾病或紊乱的方法。